Completed PHASE3 INTERVENTIONAL 1-arm NCT00254969

Immunogenicity and Safety of Pentaxim in South African Infants

Sponsor: Sanofi

Conditions Diphtheria Haemophilus Infections Pertussis Poliomyelitis Tetanus

Interventions Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib

Updated 5 times since 2017 Last updated: Apr 16, 2012 Started: Oct 31, 2005 Primary completion: May 31, 2008 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00254969, this PHASE3 trial focuses on Diphtheria and Haemophilus Infections and remains completed. Sponsored by Sanofi, it has been updated 5 times since 2005, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Soweto, South Africa